ArticleLiver cancer2020
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma.
Article in Liver cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Sorafenib nanomedicine in HCC: nano-bio interactions and combination therapies.Journal of nanobiotechnology · 2026Review
- Optimal sequencing of locoregional and systemic therapies for intermediate and advanced hepatocellular carcinoma: a network meta-analysis.Journal of cancer research and clinical oncology · 2025Review
- Immunotherapy targeting liver cancer tumor-initiating cells: challenges, mechanisms, and emerging therapeutic horizons.Frontiers in immunology · 2025Review
- Treatment Outcomes of Systemic Therapies for Infiltrative Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2025Article
- Precise In Situ Delivery of a Photo-Enhanceable Inflammasome-Activating Nanovaccine Activates Anticancer Immunity.Cancer research · 2024Article
- Transarterial Embolization Enhances Programmed Cell Death Ligand 1 Expression and Influences CD8Cardiovascular and interventional radiology · 2024Article
- Review
- A comprehensive pan-cancer analysis revealing the role of ITPRIPL1 as a prognostic and immunological biomarker.Frontiers in molecular biosciences · 2024Article
- Recurrence risk stratification of hepatocellular carcinomas based on immune gene expression and features extracted from pathological images.PLoS computational biology · 2023Article
- Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.Cancers · 2023Article
- Analysis and prediction of the efficacy and influencing factors of camrelizumab combined with TACE and sorafenib in the treatment of advanced hepatocellular carcinoma.Journal of cancer research and clinical oncology · 2023Article
- Hepatic artery intervention combined with immune-targeted therapy is superior to sequential therapy in BCLC-C hepatocellular carcinoma.Journal of cancer research and clinical oncology · 2023Article
- Prioritized Requirements for First-Line Systemic Therapy for Hepatocellular Carcinoma: Broad Benefit with Less Toxicity.Liver cancer · 2023Article
- N6-methyladenosine with immune infiltration and PD-L1 in hepatocellular carcinoma: novel perspective to personalized diagnosis and treatment.Frontiers in endocrinology · 2023Article
- Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma.Hepatobiliary surgery and nutrition · 2022Article
- Selection of Systemic Treatment Regimen for Unresectable Hepatocellular Carcinoma: Does Etiology Matter?Liver cancer · 2022Article
- How Compatible Are Immune Checkpoint Inhibitors and Thermal Ablation for Liver Metastases?Cancers · 2022Article
- Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma.Liver cancer · 2022Article
- Targets of immunotherapy for hepatocellular carcinoma: An update.World journal of hepatology · 2022Review
- Understanding the Immunoenvironment of Primary Liver Cancer: A Histopathology Perspective.Journal of hepatocellular carcinoma · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.